Martin Fan
Stock Analyst at Wedbush
(2.08)
# 1,822
Out of 4,944 analysts
7
Total ratings
42.86%
Success rate
9.22%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Martin Fan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANAB AnaptysBio | Maintains: Outperform | $40 → $45 | $20.74 | +117.02% | 2 | Aug 7, 2025 | |
| RNAC Cartesian Therapeutics | Initiates: Outperform | $38 | $11.81 | +221.76% | 1 | Jul 9, 2025 | |
| ACRS Aclaris Therapeutics | Initiates: Outperform | $8 | $1.70 | +370.59% | 1 | May 28, 2025 | |
| ORKA Oruka Therapeutics | Reiterates: Outperform | $40 | $15.30 | +161.44% | 1 | May 15, 2025 | |
| ARTV Artiva Biotherapeutics | Reiterates: Outperform | $18 | $2.67 | +574.16% | 1 | Mar 25, 2025 | |
| ZBIO Zenas BioPharma | Initiates: Outperform | $35 | $16.75 | +108.96% | 1 | Mar 20, 2025 |
AnaptysBio
Aug 7, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $20.74
Upside: +117.02%
Cartesian Therapeutics
Jul 9, 2025
Initiates: Outperform
Price Target: $38
Current: $11.81
Upside: +221.76%
Aclaris Therapeutics
May 28, 2025
Initiates: Outperform
Price Target: $8
Current: $1.70
Upside: +370.59%
Oruka Therapeutics
May 15, 2025
Reiterates: Outperform
Price Target: $40
Current: $15.30
Upside: +161.44%
Artiva Biotherapeutics
Mar 25, 2025
Reiterates: Outperform
Price Target: $18
Current: $2.67
Upside: +574.16%
Zenas BioPharma
Mar 20, 2025
Initiates: Outperform
Price Target: $35
Current: $16.75
Upside: +108.96%